Cost-effectiveness of a potential vaccine candidate for Haemophilus influenzae serotype 'a'. (Q49834339)

22 February 2018

title

Cost-effectiveness of a potential vaccine candidate for Haemophilus influenzae serotype 'a'. (English)

1 reference

22 February 2018

main subject

Haemophilus influenzae

object named as

Haemophilus influenzae

1 reference

Affan Shoukat

1 reference

22 February 2018

Robert Van Exan

series ordinal

1 reference

22 February 2018

Seyed M Moghadas

series ordinal

1 reference

22 February 2018

language of work or name

English

0 references

publication date

16 February 2018

1 reference

22 February 2018

published in

Vaccine

1 reference

22 February 2018

Haemophilus influenzae type a infection and its prevention

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Impact of routine vaccination with a conjugate Haemophilus influenzae type b vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Modeling insights into Haemophilus influenzae type b disease, transmission, and vaccine programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

School‐Aged Children: A Reservoir for Continued Circulation ofHaemophilus influenzaeType b in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

The changing epidemiology of invasive Haemophilus influenzae disease: Emergence and global presence of serotype a strains that may require a new vaccine for control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Characteristics of invasive Haemophilus influenzae serotype a (Hia) from Nunavik, Canada and comparison with Hia strains in other North American Arctic regions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Laboratory characterization of invasive Haemophilus influenzae isolates from Nunavut, Canada, 2000-2012

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Invasive Bacterial Diseases in Northern Canada, 2006-2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

A review of invasive Haemophilus influenzae disease in the Indigenous populations of North America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

The epidemiology of invasive disease due to Haemophilus influenzae serotype a in the Canadian North from 2000 to 2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Invasive bacterial diseases in northern Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Epidemiology of Haemophilus influenzae serotype a, North American Arctic, 2000-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Epidemiology of invasive pneumococcal and Haemophilus influenzae diseases in Northwestern Ontario, Canada, 2010-2015.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Haemophilus influenzae serotype a as a cause of serious invasive infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Invasive serotype a Haemophilus influenzae infections with a virulence genotype resembling Haemophilus influenzae type b: emerging pathogen in the vaccine era?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Global Epidemiology of InvasiveHaemophilus influenzaeType a Disease: Do We Need a New Vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Developing a vaccine for Haemophilus influenzae serotype a: Proceedings of a workshop.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Investigating the candidacy of a capsular polysaccharide-based glycoconjugate as a vaccine to combat Haemophilus influenzae type a disease: A solution for an unmet public health need

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Mathematical models of Haemophilus influenzae type b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Modelling transmission, immunity and disease of Haemophilus influenzae type b in a structured population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Modelling the impact of vaccination on curtailing Haemophilus influenzae serotype 'a'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Dynamics of naturally acquired antibody against Haemophilus influenzae type a capsular polysaccharide in a Canadian Aboriginal population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: regional analysis and assessment of major determinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Dynamics of natural immunity caused by subclinical infections, case study on Haemophilus influenzae type b (Hib)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Effectiveness of Haemophilus influenzae type b vaccines administered according to various schedules: systematic review and meta-analysis of observational data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Dose-specific efficacy of Haemophilus influenzae type b conjugate vaccines: a systematic review and meta-analysis of controlled clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Synthesis of octa- and dodecamers of D-ribitol-1-phosphate and their protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Confidence intervals for cost/effectiveness ratios

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Confidence Intervals for Cost-Effectiveness Ratios: A Comparison of Four Methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Median-Based Incremental Cost-Effectiveness Ratio (ICER)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Vaccine acceptance, hesitancy and refusal in Canada: Challenges and potential approaches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

Simulating Immune Interference on the Effect of a Bivalent Glycoconjugate Vaccine against Haemophilus influenzae Serotypes "a" and "b".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.01.047

10.1016/J.VACCINE.2018.01.047

7 January 2021

Identifiers

DOI

1 reference

22 February 2018

1 reference

22 February 2018